Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling
IntroductionAlpelisib, a selective PI3Kα inhibitor that targets PIK3CA mutations, is approved for hormone receptor–positive, HER2-negative breast cancer. However, its therapeutic potential in HER2-positive disease remains underexplored. Hyperglycemia, a frequent adverse event of alpelisib, limits it...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-11-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1631415/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|